Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Epidemiology of periprosthetic femoral fractures in 5417 revision total hip arthroplasties
Watts, Chad D. , Lewallen, David G. , Berry, Daniel J. , Abdel, Matthew P. , Houdek, Matthew T. , Berry, Daniel J , Pagnano, Mark W

The Bone & Joint Journal | April 1, 2016 | Volume: 98-B | Issue: 4 | Pages: 468-474

10.1302/0301-620x.98b4.37203 | PMID 27037428 Get It

Aims The goals of this study were to define the risk factors, characteristics, and chronology of fractures in 5417 revision total hip arthroplasties (THAs). Patients and Methods From our hospital’s prospectively collected database we identified all patients who had undergone a revision THA between 1969 and 2011 which involved the femoral stem. The patients’ medical records and radiographs were examined and the relevant data extracted. Post-operative periprosthetic fractures were classified using the Vancouver system. A total of 5417 revision THAs were identified. Results There were 668 intra-operative fractures, giving an incidence of 12%. Fractures were three times more common with uncemented stems (19%) than with cemented stems (6%) (p < 0.001). The incidence of intra-operative femoral fracture varied by uncemented stem type: fully-coated (20%); proximally-coated (19%); modular fluted tapered (16%) (p < 0.05). Most fractures occurred during the insertion of the femoral component (35%). One-third involved the diaphysis and 26% were of the calcar: 69% were undisplaced. There were 281 post-operative fractures of the femur (20-year probability = 11%). There was no difference in risk for cemented and uncemented stems. Post-operative fractures were more common in men < 70 years (p = 0.02). Periprosthetic fractures occurred earlier after uncemented revision of the femoral component, but later after a cemented revision. The most common fracture type was a Vancouver B 1 (31%). Of all post-operative fractures, 24% underwent open reduction and internal fixation and 15% revision arthroplasty. Conclusion In revision THA, intra-operative fractures occurred three times more often with an uncemented stem. Many were undisplaced diaphyseal fractures treated with cerclage fixation. While the risk of post-operative fracture is similar between uncemented and cemented components, they occur at notably different times depending on the type of stem fixation. Take home message: In revision THA, intra-operative periprosthetic femoral fractures occur three times more often with uncemented stems. Many are non-displaced diaphyseal fractures treated with cerclage fixation. While postoperative fracture risks are equivalent between uncemented and cemented components, they occur at notably different time periods based on stem fixation type. Cite this article: Bone Joint J 2016;98-B:468–74.
Epidemiology of periprosthetic fracture of the femur in 32 644 primary total hip arthroplasties
Watts, Chad D. , Lewallen, David G. , Abdel, Matthew P. , Houdek, Matthew T. , Berry, Daniel J. , Pagnano, Mark W

The Bone & Joint Journal | April 1, 2016 | Volume: 98-B | Issue: 4 | Pages: 461-467

10.1302/0301-620x.98b4.37201 | PMID 27037427 Get It

Aim and Methods The goals of this study were to define the risk factors, nature, chronology, and treatment strategies adopted for periprosthetic femoral fractures in 32 644 primary total hip arthroplasties (THAs). Results There were 564 intra-operative fractures (1.7%); 529 during uncemented stem placement (3.0%) and 35 during cemented stem placement (0.23%). Intra-operative fractures were more common in females and patients over 65 years (p < 0.001). The majority occurred during placement of the femoral component (60%), and involved the calcar (69%). There were 557 post-operative fractures (20-year probability: 3.5%; 95% confidence interval (CI) 3.2 to 3.9); 335 fractures after placement of an uncemented stem (20-year probability: 7.7%; 95% CI 6.2 to 9.1) and 222 after placement of a cemented stem (20-year probability: 2.1%; 95% CI 1.8 to 2.5). The probability of a post-operative fracture within 30 days after an uncemented stem was ten times higher than a cemented stem. The most common post-operative fracture type was a Vancouver A G (32%; n = 135), with 67% occurring after a fall. In all, 36% (n = 152) were treated with revision arthroplasty. Conclusion In summary, intra-operative fractures occur 14 times more often with uncemented stems. Female patients over 65 years of age are at highest risk. Post-operative fractures are also most common with uncemented stems, but are independent of age or gender. Cumulative risk of post-operative periprosthetic femur fracture was 3.5% at 20 years. Take home message: Intra-operative fractures occur 14 times more often with uncemented stems, particularly with female patients over 65 years of age, while post-operative fracture risk is independent of age or gender, but still increased with uncemented stems. Cite this article: Bone Joint J 2016;98-B:461–7.
Syncope
Cannon, Bryan C. , Wackel, Philip L. , Cannon, Bryan, Wackel, Philip

Pediatrics In Review | April 1, 2016 | Volume: 37 | Issue: 4 | Pages: 159-168

10.1542/pir.2014-0109 | PMID 27037102 Get It

Esophageal stent placement as a therapeutic option for iatrogenic esophageal perforation in children
Ahmad, Alsafadi, Song, Louis M. Wong Kee , Absah, Imad , Wong Kee Song, Louis M

Avicenna Journal of Medicine | April 1, 2016 | Volume: 06 | Issue: 02 | Pages: 51-53

10.4103/2231-0770.179552 | PMID 27144142 Get It

AbstractIatrogenic esophageal perforation (IEP) is a potentially serious adverse event of interventional endoscopy. The approach to IEP varies from surgical repair for large perforations to conservative treatment for small contained perforations. We report a case of an 18-month-old girl with congenital esophageal stenosis suffering a large esophageal perforation after a trial of stricture dilatation, which was successfully managed by the placement of fully covered stent. Hence, in selected cases, esophageal stent placement is a feasible alternative to invasive surgery in managing IEP.
Recommendations and guidelines in the JIMD: suggested procedures and avoidance of conflicts of interest
Zschocke, Johannes , Baumgartner, Matthias R. , Patterson, Marc C. , Peters, Verena, Rahman, Shamima , Morava, Éva , Patterson, Marc , Baumgartner, Matthias

Journal of Inherited Metabolic Disease | April 1, 2016 | Volume: 39 | Issue: 3 | Pages: 327-329

10.1007/s10545-016-9931-3 | PMID 27038029 Get It

First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis
Chakraborty, Rajshekhar , Novak, Anne J. , Ansell, Stephen M. , Muchtar, Eli , Kapoor, Prashant , Hayman, Suzanne R. , Lacy, Martha Q. , King, Rebecca L. , Buadi, Francis K. , Dispenzieri, Angela , Gertz, Morie A. , Muchtar, E , Chakraborty, Rajshekhar

Blood | April 1, 2016 | Volume: 127 | Issue: 23 | Pages: 2936-2938

10.1182/blood-2016-02-702035 | PMID 27034430 Get It

Bayesian Variable Selection in Multilevel Item Response Theory Models with Application in Genomics
Fragoso, Tiago M., Pereira, Alexandre C. , Rosa, Guilherme J. M. , Soler, Júlia Maria Pavan , de Andrade, Mariza, Andrade, Mariza de

Genetic Epidemiology | March 31, 2016 | Volume: 40 | Issue: 3 | Pages: 253-263

10.1002/gepi.21960 | PMID 27027518 Get It

New insights into the evaluation of randomized controlled trials for rare diseases over a long‐term research horizon: a simulation study
Bayar, Mohamed Amine , Michiels, Stefan , Deley, Marie‐Cécile Le , Sargent, Daniel J , Teuff, Gwénaël Le , Sargent, Daniel J.

Statistics in Medicine | March 31, 2016 | Volume: 35 | Issue: 19 | Pages: 3245-3258

10.1002/sim.6942 | PMID 27027783 Get It

Large sample sizes are required in randomized clinical trials designed to meet typical one‐sided 2.5% α‐level and 80% power. This may not be achievable when the disease is rare. We simulated a series of two‐arm superiority trials over a 15‐year period. The design parameters examined were the α‐level and the number of trials conducted over the 15‐year period (thus, trial sample size). Different disease severities and accrual rates were considered. The future treatment effect was characterized by its associated hazard rate; different hypotheses of how treatments improve over time were considered. We defined the total survival benefit as the relative difference of the hazard rates at year 15 versus year 0. The optimal design was defined by maximizing the expected total survival benefit, provided that the risk of selecting at year 15 a treatment inferior to the initial control treatment remains below 1%. Compared with two larger trials with typical one‐sided 2.5% α‐level, performing a series of small trials with relaxed α‐levels leads on average to larger survival benefits over a 15‐year research horizon, but also to higher risk of selecting a worse treatment at the end of the research period. Under reasonably optimistic assumptions regarding the future treatment effects, optimal designs outperform traditional ones when the disease is severe (baseline median survival ≤ 1 year) and the accrual is ≥100 patients per year, whereas no major improvement is observed in diseases with better prognosis. Trial designs aiming to maximize survival gain over a long research horizon across a series of trials are worth discussing in the context of rare diseases. Copyright © 2016 John Wiley & Sons, Ltd.
Long‐term follow‐up after PFO device closure
Taggart, Nathaniel W. , Reeder, Guy S., Lennon, Ryan J. , Slusser, Joshua P. , Freund, Monique , Cetta, Frank , Hagler, Donald J. , Freund, Monique A, Cabalka, Allison K. , Taggart, Nathaniel W

Catheterization and Cardiovascular Interventions | March 31, 2016 | Volume: 89 | Issue: 1 | Pages: 124-133

10.1002/ccd.26518 | PMID 27027873 Get It

ObjectivesTo describe medium‐ to long‐term follow‐up of patients undergoing device closure of patent foramen ovale (PFO) for stroke or transient ischemic attack (TIA).BackgroundTranscatheter device closure of PFO continues to be used for secondary prevention of cryptogenic stroke or TIA, but data are lacking regarding long‐term outcomes.MethodsWe reviewed the Mayo Clinic Rochester PFO database for patients who underwent device closure of PFO for secondary prevention of stroke/TIA from December 2001 to June 2012. Demographic, clinical, procedural, and follow‐up data were reviewed. Recurrence rate of stroke/TIA were calculated. Data were analyzed to identify risk factors of recurrent neurologic events.ResultsSeven hundred and thirty patients (mean age 53 years; 40% female) were included in our study. Most patients (72%) had cryptogenic stroke as their qualifying event for PFO closure. There were no procedure‐related deaths or strokes. The most commonly used device was the Amplatzer Septal Occluder (82%). Median follow‐up was 6 years. A 3.9% of patients had documented residual right‐to‐left shunting at last echocardiogram. Recurrent stroke and/or TIA were reported in 45 patients, (6.3% of patients with follow‐up data). Patients who experienced recurrent stroke/TIA were older and had a higher rate of diabetes and hypertension than those who did not. The presence of residual shunt did not correlate with risk of recurrent events.ConclusionsDevice closure of PFO can be performed safely with very good long‐term resolution of atrial shunting. Recurrent neurologic events after PFO closure may reflect additional comorbid risk factors unrelated to the potential for paradoxical embolism. © 2016 Wiley Periodicals, Inc.
Neuropathological basis of nonmotor manifestations of Parkinson's disease
Beach, Thomas G. , Adler, Charles H.

Movement Disorders | March 31, 2016 | Volume: 31 | Issue: 8 | Pages: 1114-1119

10.1002/mds.26605 | PMID 27030013 Get It

ABSTRACTNonmotor manifestations of Parkinson's disease (PD) can begin well before motor PD begins. It is now clear, from clinical and autopsy studies, that there is significant Lewy‐type α‐synucleinopathy present outside the nigro‐striatal pathway and that this may underlie these nonmotor manifestations. This review discusses neuropathological findings that may underlie nonmotor symptoms that either predate motor findings or occur as the disease progresses. © 2016 International Parkinson and Movement Disorder Society